Bearish
Bleichmar Fonti & Auld LLP is investigating ADMA Biologics (NASDAQ:ADMA) for alleged violations of federal securities laws after a Culper Research rep...
ADMA Biologics, Inc. reported its Q1 revenue at $114.5 million, falling short of the FactSet estimate of $140.0 million. The company is a commercial b...
Bearish
The Rosen Law Firm has announced an investigation into potential securities claims against ADMA Biologics, Inc. following allegations of misleading bu...
Mizuho has lowered its price target on ADMA Biologics Inc. (ADMA) to $24 from $30, while maintaining an Outperform rating. This adjustment comes ahead...
Bearish
Cantor Fitzgerald downgraded ADMA Biologics Inc. (ADMA) to Neutral from Overweight after discussions with investors regarding a short report alleging ...
Neutral
Mizuho has cut its price target on ADMA Biologics Inc. (ADMA) from $30 to $24, while maintaining an Outperform rating. This adjustment follows a broad...